Navigating the Central Nervous System (CNS): A Pharmacokinetic Approach to the Treatment of CNS Tumors, Glioblastoma Multiforme (GBM), in Particular.

Authors: Bartusik-Aebisher D, Tylutki J, Tylutki M, Leś D, Aebisher D

Tumors of the central nervous system (CNS) represent a unique therapeutic challenge due to the complexity of the CNS and the protective role of the blood-brain barrier (BBB). All gliomas are of glial origin, account for the majority of CNS tumors, and are classified by the World Health Organization into four grades based on malignancy. High-grade gliomas, such as glioblastoma multiforme (GBM), exhibit aggressive growth, resistance to treatment, and poor prognosis. Despite significant advancements in cancer therapy, effective drug delivery to CNS tumors remains limited due to pharmacokinetic barriers, especially the BBB, and tumor-related resistance mechanisms. This review highlights the biological characteristics of gliomas and emphasizes the current challenges in achieving effective CNS tumor treatment.

Introduction

Purpose Other

Study Objective To review the biological characteristics of gliomas and highlight the challenges, particularly the blood–brain barrier and tumor resistance mechanisms, that limit effective CNS tumor treatment.

Disease model glioma (glioblastoma multiforme)

Outcomes and Safety

Summary of Outcomes High-grade gliomas (e.g., glioblastoma) exhibit aggressive growth, resistance to therapy, and poor prognosis, and effective drug delivery is severely limited by the blood–brain barrier and tumor-related resistance mechanisms.

Safety-related matter No safety-related issues or adverse effects are reported in the provided text.

Brain Region

Visualization unavailable

Ultrasound Parameters

Focal Characteristics Focal depth: None; Focal length: None; Aperture size: None

We are open to feedback. If you see a mistake or have a suggestion, please contact us.